CNR Institutional Research Information System

MORELLI, MICAELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.854
NA - Nord America 1.463
EU - Europa 1.457
SA - Sud America 487
AF - Africa 44
OC - Oceania 1
Totale 6.306
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.415
SG - Singapore 1.167
IT - Italia 1.119
CN - Cina 727
BR - Brasile 413
HK - Hong Kong 291
VN - Vietnam 255
KR - Corea 148
FR - Francia 140
BD - Bangladesh 52
JP - Giappone 48
NL - Olanda 47
IN - India 44
AR - Argentina 27
GB - Regno Unito 26
FI - Finlandia 25
IL - Israele 24
DE - Germania 22
IQ - Iraq 18
MX - Messico 18
CA - Canada 17
ZA - Sudafrica 16
EC - Ecuador 15
TR - Turchia 13
AT - Austria 12
ID - Indonesia 11
RU - Federazione Russa 11
UZ - Uzbekistan 11
ES - Italia 8
PE - Perù 8
SA - Arabia Saudita 8
VE - Venezuela 8
MA - Marocco 7
PK - Pakistan 7
PY - Paraguay 7
LT - Lituania 6
PL - Polonia 6
SE - Svezia 6
CO - Colombia 5
CR - Costa Rica 5
EG - Egitto 5
AE - Emirati Arabi Uniti 4
KE - Kenya 4
UA - Ucraina 4
AZ - Azerbaigian 3
CH - Svizzera 3
DK - Danimarca 3
DZ - Algeria 3
IE - Irlanda 3
OM - Oman 3
TN - Tunisia 3
BG - Bulgaria 2
BH - Bahrain 2
BZ - Belize 2
CL - Cile 2
EE - Estonia 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
MY - Malesia 2
PH - Filippine 2
PS - Palestinian Territory 2
PT - Portogallo 2
RO - Romania 2
UY - Uruguay 2
BY - Bielorussia 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
JM - Giamaica 1
KG - Kirghizistan 1
MD - Moldavia 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
RS - Serbia 1
SI - Slovenia 1
SL - Sierra Leone 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
TZ - Tanzania 1
ZW - Zimbabwe 1
Totale 6.306
Salva come PNG Salva come JPEG
Città #
Santa Clara 730
Singapore 695
Cagliari 618
Hefei 363
Hong Kong 288
Rome 170
San Jose 153
Seoul 146
Lauterbourg 128
Beijing 116
Ashburn 97
Ho Chi Minh City 89
Hanoi 67
Los Angeles 56
Uta 53
Sassoferrato 43
Dallas 36
São Paulo 32
Tokyo 27
San Benedetto del Tronto 22
Helsinki 20
Minamishinagawa 20
Bengaluru 19
Rio de Janeiro 19
Florence 17
New York 16
Buffalo 15
Naples 15
Sesto Fiorentino 14
Vaglia 14
Tashkent 11
Brasília 10
Da Nang 10
Matera 10
Porto Alegre 10
Guarulhos 9
Milan 9
Sassari 9
Nuremberg 8
Olbia 8
Baghdad 7
Belo Horizonte 7
Boardman 7
Dhaka 7
Guangzhou 7
Guayaquil 7
Haiphong 7
Johannesburg 7
Nuoro 7
Biên Hòa 6
Cabras 6
Frankfurt am Main 6
Thái Bình 6
Brooklyn 5
City of London 5
Cosenza 5
Erbil 5
Giulianova 5
Hải Dương 5
Lappeenranta 5
Lima 5
Manaus 5
Nha Trang 5
Poplar 5
Quartu Sant'Elena 5
Salvador 5
Sorocaba 5
Stockholm 5
Toronto 5
Turin 5
Vienna 5
Atlanta 4
Cairo 4
Curitiba 4
Denver 4
Feira de Santana 4
Goiânia 4
London 4
Nairobi 4
Orem 4
Phoenix 4
Quito 4
Quận Bình Thạnh 4
Recife 4
Ribeirão Preto 4
San José 4
Santo André 4
Shanghai 4
Uberlândia 4
Udine 4
Volla 4
Warsaw 4
Aracaju 3
Baku 3
Campo Grande 3
Casablanca 3
Caserta 3
Catania 3
Charlotte 3
Chennai 3
Totale 4.477
Salva come PNG Salva come JPEG
Nome #
Early α-synuclein/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease 1.094
MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex 103
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT1A/1B receptor agonist and A2A receptor antagonist 85
Modulatory role of adenosine A(2A) receptors in basal ganglia as basis for the use of A(2A) antagonists in the treatment of Parkinson's disease 77
Receptor Antagonism and Dyskinesia in Parkinson's Disease 72
RECEPTOR ANTAGONISTS IMPROVE AKINESIA AND SENSORY-MOTOR DEFICITS IN THE 6-HYDROXYDOPAMINE MODEL OF PARKINSON S DISEASE 72
Behavioural characterization of engrailed mutant mice as model of Parkinson's disease 70
Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson's disease 70
PRIMING OF 6-HYDROXYDOPAMINE-LESIONED RATS WITH L-DOPA OR QUINPIROLE RESULTS IN AN INCREASE IN DOPAMINE D1 RECEPTOR-DEPENDENT CYCLIC AMP PRODUCTION IN STRIATAL TISSUE 68
Withania somnifera influences MDMA-induced hyperthermic, cognitive, neurotoxic and neuroinflammatory effects in mice 68
Lack of rhes increases mdma-induced neuroinflammation and dopamine neuron degeneration: Role of gender and age 67
C-FOS EXPRESSION AS A MOLECULAR MARKER IN CORTICOTROPIN-RELEASING FACTOR-INDUCED SEIZURES 66
ADENOSINE A2A ANTAGONISTS AND PARKINSON S DISEASE: NEW FINDINGS ON PARKINSONIAN TREMOR 63
Modulation of Rat 50-kHz Ultrasonic Vocalizations by Glucocorticoid Signaling: Possible Relevance to Reward and Motivation 62
ADENOSINE A2A RECEPTOR AGONISTS INCREASE FOS-LIKE IMMUNOREACTIVITY IN MESOLIMBIC AREAS 60
. Interaction between metabotropic adenosina A2A and glutamate MGLU5 receptors in parkinsonian-like muscle rigidity and tremor 60
In utero exposure to dexamethasone causes a persistent and age-dependent exacerbation of the neurotoxic effects and glia activation induced by MDMA in dopaminergic brain regions of C57BL/6J mice 60
Fos expression induced by olanzapine and risperidone in the central extended amygdala 59
Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson's Disease 59
Involvement of the protein ras homolog enriched in the striatum, rhes, in dopaminergic neurons' degeneration: Link to parkinson's disease 56
Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems 56
Symptomatic efficacy of mucuna pruriens seed extract in rodent model of Parkinson s disease 55
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage 54
Decreased striatal adenosine extracellular levels and increased A2A receptors mRNA after dopamine denarvation 53
Extract from Nasco pomace loaded in nutriosomes exerts anti-inflammatory effects in the MPTP mouse model of Parkinson's disease 53
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility 52
A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A(2A) Receptor Antagonists 52
Serotonin 5-HT1A receptors and their interactions with adenosine A2A receptors in Parkinson's disease and dyskinesia 52
SUBCHRONIC-INTERMITTENT CAFFEINE AMPLIFIES THE MOTOR EFFECTS OF AMPHETAMINE IN RATS 50
Neurobiology of Parkinson's Disease 49
Combined administration of dopaminergic and nondopaminergic drugs reverses neuroinflammation in a rat model of parkinson's disease 48
Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity 48
Control of Motor Function by Adenosine A2A Receptors in Parkinson's and Huntington's Disease 46
'Priming' to dopamine agonist-induced contralateral turning as a model of non-associative sensitization to the expression of the post-synaptic dopamine message 45
MDMA ADMINISTRATION DURING ADOLESCENCE EXACERBATES MPTP-INDUCED COGNITIVE IMPAIRMENT, NEURODEGENERATION AND NEUROINFLAMMATION IN MOTOR, LIMBIC AND CORTICAL AREAS 45
Rhes counteracts dopamine neuron degeneration and neuroinflammation depending on gender and age 45
A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson’s Disease 44
EFFICACY OF RASAGILINE ON PROGRESSIVE DOPAMINE NEURON DEGENERATION AND NEUROINFLAMMATION IN A CHRONIC MPTPP MODEL OF PARKINSON'S DISEASE 43
Adenosine A(2A) receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. 42
The 6-hydroxydopamine model of Parkinson's disease 42
Neuroinflammation and activation of Zif-268 in dyskinetic 6-OHDA-lesioned rats is counteracted by association of a 5-HT1A/1B receptor agonist and an A(2A) receptor antagonist 42
Influence of dopamine transmission in the medial prefrontal cortex and dorsal striatum on the emission of 50-kHz ultrasonic vocalizations in rats treated with amphetamine: Effects on drug-stimulated and conditioned calls 41
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A)receptor antagonists 39
Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms 39
Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects 38
ADENOSINE A2A RECEPTOR ANTAGONIST TREATMENT OF PARKINSON S DISEASE. In The basal ganglia pathophysiology: recent advances 37
Role of adenosine A(2A) receptors in motor control: relevance to Parkinson's disease and dyskinesia 37
Neurofarmacologia nel trattamento della Malattia di Parkinson e nuovi approcci farmacologici 37
Therapeutic potential and antidyskinetic activity of the combined antagonism of adenosine A2A receptors and stimulation of 5HT1A/1B receptors in models of Parkinson's disease: acute and chronic studies. 37
Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists 36
Novel therapeutic strategy for the control of dyskinesia in the therapy of Parkinson's disease 36
Caffeine consumption and changes in the function of dopaminergic transmission: Evidence of a hyperdopaminergic state in rats subchronically treated with caffeine 36
INDUCTION OF FOS-LIKE IMMUNOREACTIVITY IN THE CENTRAL EXTENDED AMYGDALA BY ANTIDEPRESSANT DRUGS 35
A2A receptor antagonists improve akinesia and sensory-motor deficits in the 6-hydroxydopamine model of Parkinson's disease 35
A novel therapeutic strategy to prevent the onset of dyskinesia in models of Parkinson's disease: acute and chronic studies. 34
Farmaci Antiparkinsoniani ed Attivi in altri disturbi motori 34
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA pretreated mice 33
Behavioral and biochemical characterization as antiparkinsonian drug of the new adenosine A2A antagonist 8-ethoxy-9-ethyladenine 33
Model of dyskinesia in 6-hydroxydopamine-lesioned rats: validity of sensitization in turning behaviour and abnormal involuntary movements. 33
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 32
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats 32
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists 32
The Small GTP-Binding Protein Rhes Influences Nigrostriatal-Dependent Motor Behavior During Aging 32
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats 31
MOTOR STIMULANT EFFECTS OF THE ADENOSINE A2A RECEPTOR ANTAGONIST SCH 58261 DO NOT DEVELOP TOLERANCE AFTER REPEATED TREATMENTS IN 6-HYDROXYDOPAMINE-LESIONED RATS 31
M. Morelli, N. Simola, A. Pinna, S. Pontis 31
Symptomatic and neuroprotective effects of A2A receptor antagonists in Parkinson's disease 30
Interaction between antagonists of adenosine A2A receptors and agonists of serotonin 5-HT1A/B receptors: a novel therapeutic strategy for the control of dyskinesia in the therapy of Parkinson's disease 30
Metformin Prevented Dopaminergic Neurotoxicity Induced by 3,4-Methylenedioxymethamphetamine Administration 30
Blockade of muscarinic receptors potentiates D1 dependent turning behavior and c-fos expression in 6-hydroxydopamine-lesioned rats but does not influence D2 mediated responses 30
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease 30
Behavioural Correlates of Dopaminergic Agonists' Dyskinetic Potential in the 6-OHDA-Lesioned Rat 30
Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry 29
INTERACTION BETWEEN DOPAMINE AND ADENOSINE A2A RECEPTORS AS A BASIS FOR THE TREATMENT OF PARKINSON'S DISEASE 29
Assessment of Symptomatic and Neuroprotective Efficacy of Mucuna Pruriens Seed Extract in Rodent Model of Parkinson's Disease 29
Blockade of NMDA receptors differentially affects D-1 and D-2 mediated turning behavior in the 6-hydroxydopamine model of Parkinson 29
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. 29
MODULATORY ROLE OF ADENOSINE A2A RECEPTORS AS BASIS FOR THE USE OF A2A ANTAGONISTS IN THE TREATMENT OF PARKINSON S DISEASE 29
Different patterns of behavior and gene expression induced by chronic L-dopa and A(2A) antagonists plus L-DOPA treatments in 6-hydroxydopamine lesioned rats 28
Protective Agents in Parkinson's Disease: Caffeine and Adenosine A2A Receptor Antagonists 28
Effect of crowding, temperature and age on glia activation and dopaminergic neurotoxicity induced by MDMA in the mouse brain 28
Influence of caffeine on 3,4-methylenedioxymethamphetamine-induced dopaminergic neuron degeneration and neuroinflammation is age-dependent 28
Methylxanthines and drug dependence: a focus on interactions with substances of abuse 28
Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction 28
Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: Possible relevance to reward and motivation 28
L-Dopa stimulates c-fos expression in dopamine denervated striatum by combined activation of D-1 and D-2 receptors 28
A novel therapeutic strategy for the prevention of the onset of dyskinesia in the therapy of Parkinson's disease 27
ATTENUATION OF MPTP-INDUCED NEURODEGENERATION BY NCX 2216, A NITRIC OXIDE-RELEASING DERIVATIVE OF FLURBIPROFEN 27
Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions 27
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression 27
Caffeine consumption and Changes in the function of dopaminergic transmission: evidence of a hyperdopaminergic state in rats subchronically treated with caffeine. Published in Advances in psychology research 27
BLOCKADE OF A2a ADENOSINE RECEPTORS POSITIVELY MODULATES TURNING BEHAVIOUR AND c-FOS EXPRESSION INDUCED BY D1 AGONISTS IN DOPAMINE-DENERVATED RATS 27
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's disease 26
Sanna E, Talani G, Obili N, Mascia MP, Mostallino MC, Secci PP, Pisu MG, Biggio F, Utzeri C, Olla P, Biggio G, Follesa P. Voluntary Ethanol Consumption Induced by Social Isolation Reverses the Increase of ±(4)/´ GABA(A) Receptor Gene Expression and Functi 26
Sensitisation in turning behaviour and abnormal involuntary movements in 6-hydroxydopamine lesioned rats: Influence of the environment in which tests are performed 26
FARMACI ANTIPARKINSONIANI ED ATTIVI IN ALTRI DISTURBI MOTORI, vol. 30 del Trattato di Farmacologia 26
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioural and biochemical characterization as an antiparkinsonian drug 26
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. 25
Opposite effects of NMDA receptor blockade on dopaminergic D1- and D2- mediated behavior in the 6-hydroxydopamine model of turning: Relationship with c-fos expression 25
Behavioral, Neurochemical, and Electrophysiological Changes in an Early Spontaneous Mouse Model of Nigrostriatal Degeneration 25
Totale 5.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.505
article - articoli 14.454
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.193
Totale 35.152
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20249 0 0 0 0 0 0 0 0 2 0 1 6
2024/20252.201 7 10 162 87 628 141 49 52 32 70 525 438
2025/20264.164 278 391 435 530 638 149 588 286 253 262 229 125
Totale 6.374